Keiichiro Honma
Papers
1
Total Citations
13
H-Index
1
About
Keiichiro Honma is a leading clinical investigator in gastrointestinal oncology, with a focused expertise in gastric and gastroesophageal junction cancers. His major contributions center on the real-world safety and efficacy of emerging targeted therapies, particularly for HER2-negative, CLDN18.2-positive advanced disease. Dr. Honma’s most cited work, a 2025 case series, provides critical post-marketing surveillance data on zolbetuximab, revealing a previously underreported adverse event: protein-losing enteropathy. This finding, drawn from the GLOW and SPOTLIGHT trial populations, has immediate clinical significance, alerting oncologists to a serious complication that can arise even when the therapy extends survival. By documenting these rare toxicities, his research directly informs patient management and risk stratification in routine practice. With 13 citations for this pivotal report, Dr. Honma’s work bridges the gap between controlled trial results and real-world patient care, establishing him as a key voice in optimizing treatment sequencing and safety monitoring for advanced gastric cancer. His contributions are essential reading for clinicians navigating the expanding landscape of CLDN18.2-directed therapies.
Research Focus
Key Achievements
Top Papers
- 1